At the beginning of 2021, Prof. Renvall when asked What do you study and why? answered:

“I study healthy and diseased brain using functional neuroimaging to enable us to use healthy brains to better understand diseased ones, and to use sick ones to better understand healthy ones. (…)

I seek to combine methodological developments with practical brain imaging to improve the accuracy and effectiveness of measurements. Computational methods help in the interpretation of the results, especially when the data is challenging to collect.”

AI-Mind aims at developing Artificial Intelligence (AI) -based tools for people with Mild Cognitive Impairment (MCI) who are at risk of developing dementia. In AI-Mind we are using different methods to study brain functionality, including electroencephalogram (EEG) and magnetoencephalogram (MEG).

In the work package led by Prof. Renvall, teams are bringing together and implementing different analysing methods for data we are collecting through EEG and MEG screening of people with MCI. One of the strengths and opportunities of the AI-Mind project is the amount of neuroimaging data to be analysed, which is often a bottleneck for developing novel and functional neuroimaging tools for clinical use.

For her work within the project, Prof. Renvall was recently recognised by Mediuutiset as one of the top 10 Care and Treatment Developers in the health sector in 2021.

Mediuutiset is the leading Finnish medical magazine, which for 20 years now has been publishing the “top 100”, a list of the most influential people in health care. Care and Treatment Developers is one of 10 different categories considered in the ranking.

Interview with Prof. Hanna Renvall from January 2021 is available here.